Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results

Linde de Wijs, Corine Schreurs, Anne Schlösser, Tamar Nijsten, Dirk Jan Hijnen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Downloads (Pure)



Baricitinib is the first JAK inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse. 


To evaluate the effectiveness and safety of baricitinib treatment in daily practice in AD patients who have inadequately responded to dupilumab. 


In this prospective observational cohort study, AD patients who failed dupilumab treatment and started baricitinib treatment in context of standard care at the Erasmus MC (the Netherlands) were included. We analysed physician-reported scores and patient-reported outcome measure scores (PROMs). 


Twenty-five patients were included. Baricitinib treatment resulted in significant improvement of Eczema Area and Severity Index (EASI) scores and PROMs. Seven patients showed a good and sustained response (EASI50), eight patients showed no response (<EASI50), and five patients showed an initial response but worsening of EASI scores in time. Overall, baricitinib was well tolerated. Four patients discontinued baricitinib treatment due to ineffectiveness or side effects. 


Baricitinib can be an effective treatment for a subset of AD patients who failed dupilumab treatment in daily practice. We found three different treatment response groups including responders, temporarily responders, and non-responders.

Original languageEnglish
Pages (from-to)364-371
Number of pages8
JournalJEADV Clinical Practice
Issue number4
Publication statusPublished - Dec 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.


Dive into the research topics of 'Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results'. Together they form a unique fingerprint.

Cite this